<DOC>
	<DOCNO>NCT01444404</DOCNO>
	<brief_summary>First human , open-label , sequential dose escalation expansion study AMG 820 subject advance solid tumor .</brief_summary>
	<brief_title>A Study AMG 820 Subjects With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Men woman ≥ 18 year old Subjects must pathologically document , definitively diagnose , advance solid tumor Measurable disease per RECIST 1.1 guideline Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 Part 2 Dose Expansion : Subjects must tumor tissue accessible core needle biopsy use minimally invasive procedure must consent undergo biopsy tumor Able fast 4 6 hour FDGPET/CT scan , except subject prostate bladder cancer Competent sign date Institutional Review Board approve inform consent form Adequate hematologic , renal hepatic function determine laboratory blood urine test Men woman reproductive potential , unwilling practice highly effective method birth control duration study additional 4 month receive last dose study drug . Women lactating/breastfeeding plan become pregnant duration study Primary central nervous system ( CNS ) tumor CNS metastasis History presence hematological malignancy History arterial venous thrombosis within 6 month study enrollment History bleeding diathesis Myocardial infarction within 6 month study day 1 , symptomatic congestive heart failure ( New York Heart Association &gt; class II ) , unstable angina , unstable cardiac arrhythmia require medication , uncontrolled hypertension Hypertension adequately control medication ( diastolic &gt; 90mmHG ; systolic &gt; 140 mmHG ) Left ventricular ejection fraction ( LVEF ) ≤ 50 % Active infection requiring ( IV ) antibiotic within 2 week study enrollment Known positive test human immunodeficiency virus ( HIV ) Known chronic hepatitis B hepatitis C infection Positive test hepatitis B surface antigen hepatitis C antibody Known history tuberculosis ( TB ) , exposure active TBinfected individual , positive TB skin test ( tuberculin purify protein derivative ( PPD ) test ) upon study entry ( subject previously vaccinate TB exclude unless evidence active TB ) Antitumor therapy within 4 week study day 1 include chemotherapy , antibody therapy , retinoid therapy , investigational agent Concurrent prior anticoagulation therapy within 28 day study day 1 Major surgery within 28 day study day 1 Any comorbid medical disorder may increase risk toxicity , opinion investigator sponsor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Solid Tumors</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Clinical Trial</keyword>
</DOC>